Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Dyne Therapeutics, Inc.
- Duchenne muscular dystrophy (DMD) amenable to exon 51 skippingCash runway at this date: 10mo
- Z-RostudirsenPDUFADuchenne muscular dystrophy (DMD) amenable to exon 51 skippingCash runway at this date: 10mo
Trials need funding. See this company's dilution risk and cash position.
- Phase 3Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
zeleciment basivarsen (DYNE-101), Placebo
Myotonic Dystrophy Type 1 (DM1), DM1 +3
NCT07486934Enrollment150StartMay 2026Primary CompletionJul 2028est.CompletionJan 2029est. - Phase 3Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
Zeleciment Rostudirsen (DYNE-251), Placebo
Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne +11
NCT07608432Enrollment90StartJun 2026est.Primary CompletionDec 2030est.CompletionOct 2032est. - Phase 1/2Active, not recruiting
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
DYNE-101, Placebo
Myotonic Dystrophy Type 1 (DM1)
NCT05481879Enrollment127StartSep 2022Primary CompletionJul 2029est.CompletionJul 2029est. - Phase 1/2Active, not recruiting
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
DYNE-251, Placebo
Duchenne Muscular Dystrophy (DMD)
NCT05524883Enrollment86StartAug 2022Primary CompletionSep 2031est.CompletionSep 2031est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 3 | Recruiting | zeleciment basivarsen (DYNE-101), Placebo | NCT07486934 |
| Phase 3 | Recruiting | Zeleciment Rostudirsen (DYNE-251), Placebo | NCT07608432 |
| Phase 1/2 | Active, not recruiting | DYNE-101, Placebo | NCT05481879 |
| Phase 1/2 | Active, not recruiting | DYNE-251, Placebo | NCT05524883 |